Pepticker
Live
BPC-157 $2.80/mg— flat|Tirzepatide $2.08/mg— flat|Semaglutide $1.95/mg— flat|Retatrutide $2.90/mg— flat|TB-500 $3.40/mg— flat|MOTS-C $2.48/mg— flat|GHK-Cu $0.27/mg— flat|Cagrilintide $8.80/mg— flat|BPC-157 $2.80/mg— flat|Tirzepatide $2.08/mg— flat|Semaglutide $1.95/mg— flat|Retatrutide $2.90/mg— flat|TB-500 $3.40/mg— flat|MOTS-C $2.48/mg— flat|GHK-Cu $0.27/mg— flat|Cagrilintide $8.80/mg— flat|
·prostamax

Prostamax: Research Overview

By Pepticker Editorial, Editorial teamMedically reviewed by Pending Clinical Review, Reviewer pending

Prostamax is a synthetic tetrapeptide bioregulator with the amino acid sequence Lys-Glu-Asp-Pro (KEDP). It was developed at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson through directed synthesis from analysis of natural polypeptide fractions derived from prostate tissue. The name Prostamax is sometimes used to refer to both the synthetic tetrapeptide and the broader prostate peptide bioregulator complex (Prostatilen) associated with it. Prostamax as a standalone KEDP tetrapeptide has no FDA, EMA, or other Western regulatory approval.

What is Prostamax?

Prostamax occupies a dual identity in the literature. In some Russian clinical contexts, Prostamax or Prostatilen refers to the bovine prostate polypeptide extract used in treating chronic prostatitis. In the Khavinson bioregulator supplement program, Prostamax specifically denotes the synthetic KEDP tetrapeptide, positioned as a concentrated tissue-targeted bioregulator for prostate health maintenance. As with other Khavinson peptides, the proposed mechanism involves epigenetic modulation of prostate-cell gene expression rather than receptor-mediated pharmacology.

Proposed Mechanism

The Khavinson group proposes that the KEDP sequence binds DNA regulatory elements in prostate epithelial cells, inducing partial heterochromatin decondensation and restoring transcriptional access to genes that become silenced with age or during inflammatory states. In vitro lymphocyte chromatin studies observed that Prostamax-treated samples from aged subjects showed structural chromatin changes consistent with decondensation, suggesting a systemic or indirect epigenetic influence beyond the prostate alone (PMID referenced in Khavinson 2004 Bull Exp Biol Med). Separately, rodent prostatitis models reported reduced glandular inflammation histologically following peptide administration.

Research Summary

A study by Meskhi and Khavinson (Biofizika, 2004) examined the effect of Prostamax on heterochromatin in human lymphocytes in situ and reported chromatin structural changes. Khavinson and colleagues also published findings in Bulletin of Experimental Biology and Medicine (2004, PMID 14992297) on the effects of short peptides including KEDP on lymphocyte chromatin in elderly subjects. Borovskaya et al. (2013) conducted an experimental study in rats on Prostamax efficacy in chronic aseptic prostatitis, reporting reduced prostate swelling, decreased vascular congestion, and diminished inflammatory cell infiltration in treated animals.

Research on Prostamax is concentrated in a single Russian research group; independent Western replication is limited. The available literature consists of in vitro chromatin studies and animal prostatitis models. No randomized controlled trials in human prostatitis, benign prostatic hyperplasia, or any other prostate condition have been published in peer-reviewed Western journals. Findings from rat models of inflammation cannot be reliably extrapolated to clinical outcomes in humans.

Reported Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

No validated human dose has been established in Western dose-ranging studies. Russian-language supplement and clinical documentation associated with the Prostatilen/Prostamax complex references rectal suppositories at 30 mg or subcutaneous injections of synthetic KEDP at approximately 0.5-1 mg per day for 10-day courses. These figures are not the product of Western-standard clinical pharmacology studies.

Frequently Asked Questions

Is Prostamax the same as Prostatilen?

They are related but distinct. Prostatilen is the natural bovine prostate polypeptide complex, approved as a pharmaceutical in Russia for prostatitis. Prostamax in the Khavinson bioregulator supplement line refers to the synthetic KEDP tetrapeptide derived from analysis of the Prostatilen complex. The synthetic version is not an approved drug in any Western country.

Can Prostamax treat benign prostatic hyperplasia (BPH)?

There is no clinical trial evidence to support this claim. BPH is a structural condition with established pharmaceutical and surgical treatments. No controlled trial has evaluated Prostamax (KEDP tetrapeptide) for BPH. Patients with BPH should consult a urologist about evidence-based treatment options.

What is the evidence quality for Prostamax?

Very early stage. The published evidence consists of in vitro chromatin assays and one rat prostatitis experiment from a single Russian research laboratory. No independent replication by external groups has been published, and no human clinical trials meeting Western regulatory standards have been conducted.

References

1. Khavinson VKh, Lezhava TA, Malinin VV. Effects of short peptides on lymphocyte chromatin in senile subjects. Bull Exp Biol Med. 2004 Jan;137(1):78-81. https://pubmed.ncbi.nlm.nih.gov/14992297/

2. Meskhi A, Khavinson VKh. The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ. Biofizika. 2004 Nov-Dec;49(6):1091-3.

3. Borovskaya TG et al. Experimental studying of the drug efficiency Prostamax in the therapy of chronic aseptic prostatitis and its complications. 2013.